Business Context and Reporting Period
Anzu Special Acquisition Corp. I filed this Form 8-K on September 27, 2023, reporting the results of its special stockholder meeting regarding its proposed business combination with Envoy Medical Corporation, a medical-device company. The transaction would result in Envoy becoming a wholly owned subsidiary and the combined company being renamed Envoy Medical, Inc.
Key Financial and Capitalization Information
This filing does not provide operating revenue, profit, cash flow, margin, debt, or liquidity metrics. As of the September 5, 2023 record date, 4,312,774 shares of Class A common stock and 10,625,000 shares of Class B common stock were outstanding. The Nasdaq proposal authorizes issuance of up to 15,000,000 Class A shares to Envoy shareholders and between 4,500,000 and 5,500,000 shares of Series A preferred stock to Anzu SPAC GP I LLC and GAT Funding, LLC, including Class A shares issuable upon conversion.
Material Changes and Transaction Developments
- Stockholders approved the business combination proposal by 13,116,546 votes for, 17,543 against, and no abstentions.
- Stockholders approved the proposed charter, governance provisions, Nasdaq issuance, 2023 equity incentive plan, and employee stock purchase plan.
- Seven directors were elected to the post-combination board, each receiving 10,575,000 votes for and no votes withheld.
- The proposed charter increases authorized capital stock from 441,000,000 shares to 500,000,000 shares, consisting of 400,000,000 common shares and 100,000,000 preferred shares.
- The company expects the business combination to close on September 29, 2023, subject to satisfaction or waiver of remaining closing conditions.
- Following closing, the company intends to change its name to Envoy Medical, Inc. and expects its Class A common stock and warrants to trade on Nasdaq under the symbols COCH and COCHW, respectively.
- The previously scheduled September 29, 2023 extension meeting was canceled because the transaction was expected to close before the September 30, 2023 business-combination deadline. Consequently, the company stated that it would not complete the related redemption of Class A shares submitted in connection with the extension proposal.
Outlook, Risks, and Unusual Items
Management’s transaction timing, anticipated Nasdaq listing, and expected benefits of the combination are forward-looking statements, not guarantees. Key risks include failure to satisfy closing conditions or termination of the merger agreement; post-closing operating performance; medical-device regulatory and clinical-development uncertainty; competition; supplier and production disruptions; financing and capital availability; retention of key personnel; intellectual-property protection; legal and regulatory proceedings; inflation and interest-rate changes; and the ability to maintain Nasdaq listing standards.
The filing also notes that the board did not obtain a third-party fairness opinion and that directors’ financial and other interests may have influenced approval of the transaction. Redemption rights depend on properly demanding redemption in accordance with the applicable procedures.
Important Facts for Investors to Verify
- Whether the business combination actually closed on or around September 29, 2023 and whether all closing conditions were satisfied or waived.
- The final number of shares and preferred shares issued, including any conversions, redemptions, or dilution.
- The amount remaining in the trust account and the combined company’s post-closing cash, debt, and liquidity.
- Whether the securities began trading under COCH and COCHW and whether Nasdaq listing requirements were maintained.
- Envoy’s regulatory, clinical, commercialization, financing, and intellectual-property status after the transaction.